Abeona Therapeutics(us:ABEO)

    5.64

    -1.05%

    Updated on 2024-12-23

    Open:5.68
    Close:5.64
    High:5.72
    Low:5.58
    Pre Close:5.70
    Volume:137190.00
    Amount:773744.38
    Turnover:0.32%
    Shares:43.47M
    MarketCap:245.18M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-30673361266680.68%122528
    2024-03-31631444938452.45%152318
    2023-12-31541414068853.31%141517
    2023-09-30461247703450.49%91411
    2023-06-3042939280243.73%9813
    2023-03-3145752588941.98%41018
    2022-12-3144817413346.13%19910
    2022-09-3046210497327.44%5333
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Adage Capital Partners Gp, L.L.C.324999411.80%0
    2024-03-31Nantahala Capital Management, Llc23106408.39%603882.68%
    2024-03-31Millennium Management Llc19865487.21%56787340.03%
    2024-03-31Western Standard Llc13614894.94%55337768.48%
    2024-03-31Vanguard Group Inc11019584.00%8270.07%
    2024-03-31Ikarian Capital, Llc8885933.23%28859348.10%
    2024-03-31Laurion Capital Management Lp6468302.35%646830
    2024-03-31Citigroup Inc4840541.76%337077.49%
    2024-03-31Boothbay Fund Management, Llc2703400.98%11008068.69%
    2024-03-31Walleye Capital Llc2661140.97%7809841.54%

    About

    Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
    Address:6555 Carnegie Avenue,4th floor

    Market Movers